Serologic survey for control of hepatitis C in haemodialysis patients: Third-generation assays and analysis of costs

F. Fabrizi, G. Lunghi, L. Raffaele, I. Guarnori, G. Bacchini, M. Corti, A. Pagano, G. Erba, F. Locatelli

Research output: Contribution to journalArticle

Abstract

There is little information about the serologic survey for control of hepatitis C by using third-generation assays among chronic haemodialysis (HD) patients, and no analysis of costs has been made to this end. A serologic survey for control of hepatitis C was performed in 190 HD patients attending a single dialysis unit, using second- and third-generation assays. Costs of both serologic surveys were calculated. Anti-HCV prevalence tested by third-generation assays increased from 25% (48/190) to 28% (53/190) compared to second-generation testing; 56% (9/16) of patients showing uncertain findings by second-generation tests gave unequivocal results by third-generation assays; median duration of HD treatment and raised aminotransferase levels were positively associated (P = 0.004 and P = 0.012, respectively) with anti-HCV detected by third-generation assays. The serologic survey for control of hepatitis C in HD patients at our centre was slightly more expensive by third-generation assays compared to second-generation testing (US$ 18,866 vs US$ 17,200 per year). In summary, the use of third-generation tests largely clarified the uncertain results of second-generation tests; new additional positive patients were detected by third-generation assays compared to second-generation testing. Third-generation assays showed the association of duration of HD treatment and raised aminotransferase levels with anti-HCV antibody, as previously found by first- and second-generation assays. To date, third-generation screening and confirmatory assays seem extremely useful in the serologic survey for control of hepatitis C in HD centres without a considerable outlay.

Original languageEnglish
Pages (from-to)298-303
Number of pages6
JournalNephrology Dialysis Transplantation
Volume12
Issue number2
DOIs
Publication statusPublished - Feb 1997

Fingerprint

Hepatitis C
Renal Dialysis
Costs and Cost Analysis
Transaminases
Hepatitis C Antibodies
Surveys and Questionnaires
Dialysis
Therapeutics

Keywords

  • Analysis of costs
  • Haemodialysis patients
  • Third-generation HCV confirmatory assays
  • Third-generation HCV screening assays

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Serologic survey for control of hepatitis C in haemodialysis patients : Third-generation assays and analysis of costs. / Fabrizi, F.; Lunghi, G.; Raffaele, L.; Guarnori, I.; Bacchini, G.; Corti, M.; Pagano, A.; Erba, G.; Locatelli, F.

In: Nephrology Dialysis Transplantation, Vol. 12, No. 2, 02.1997, p. 298-303.

Research output: Contribution to journalArticle

Fabrizi, F. ; Lunghi, G. ; Raffaele, L. ; Guarnori, I. ; Bacchini, G. ; Corti, M. ; Pagano, A. ; Erba, G. ; Locatelli, F. / Serologic survey for control of hepatitis C in haemodialysis patients : Third-generation assays and analysis of costs. In: Nephrology Dialysis Transplantation. 1997 ; Vol. 12, No. 2. pp. 298-303.
@article{c245443039b748b6b3ac75ce1e1618a7,
title = "Serologic survey for control of hepatitis C in haemodialysis patients: Third-generation assays and analysis of costs",
abstract = "There is little information about the serologic survey for control of hepatitis C by using third-generation assays among chronic haemodialysis (HD) patients, and no analysis of costs has been made to this end. A serologic survey for control of hepatitis C was performed in 190 HD patients attending a single dialysis unit, using second- and third-generation assays. Costs of both serologic surveys were calculated. Anti-HCV prevalence tested by third-generation assays increased from 25{\%} (48/190) to 28{\%} (53/190) compared to second-generation testing; 56{\%} (9/16) of patients showing uncertain findings by second-generation tests gave unequivocal results by third-generation assays; median duration of HD treatment and raised aminotransferase levels were positively associated (P = 0.004 and P = 0.012, respectively) with anti-HCV detected by third-generation assays. The serologic survey for control of hepatitis C in HD patients at our centre was slightly more expensive by third-generation assays compared to second-generation testing (US$ 18,866 vs US$ 17,200 per year). In summary, the use of third-generation tests largely clarified the uncertain results of second-generation tests; new additional positive patients were detected by third-generation assays compared to second-generation testing. Third-generation assays showed the association of duration of HD treatment and raised aminotransferase levels with anti-HCV antibody, as previously found by first- and second-generation assays. To date, third-generation screening and confirmatory assays seem extremely useful in the serologic survey for control of hepatitis C in HD centres without a considerable outlay.",
keywords = "Analysis of costs, Haemodialysis patients, Third-generation HCV confirmatory assays, Third-generation HCV screening assays",
author = "F. Fabrizi and G. Lunghi and L. Raffaele and I. Guarnori and G. Bacchini and M. Corti and A. Pagano and G. Erba and F. Locatelli",
year = "1997",
month = "2",
doi = "10.1093/ndt/12.2.298",
language = "English",
volume = "12",
pages = "298--303",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Serologic survey for control of hepatitis C in haemodialysis patients

T2 - Third-generation assays and analysis of costs

AU - Fabrizi, F.

AU - Lunghi, G.

AU - Raffaele, L.

AU - Guarnori, I.

AU - Bacchini, G.

AU - Corti, M.

AU - Pagano, A.

AU - Erba, G.

AU - Locatelli, F.

PY - 1997/2

Y1 - 1997/2

N2 - There is little information about the serologic survey for control of hepatitis C by using third-generation assays among chronic haemodialysis (HD) patients, and no analysis of costs has been made to this end. A serologic survey for control of hepatitis C was performed in 190 HD patients attending a single dialysis unit, using second- and third-generation assays. Costs of both serologic surveys were calculated. Anti-HCV prevalence tested by third-generation assays increased from 25% (48/190) to 28% (53/190) compared to second-generation testing; 56% (9/16) of patients showing uncertain findings by second-generation tests gave unequivocal results by third-generation assays; median duration of HD treatment and raised aminotransferase levels were positively associated (P = 0.004 and P = 0.012, respectively) with anti-HCV detected by third-generation assays. The serologic survey for control of hepatitis C in HD patients at our centre was slightly more expensive by third-generation assays compared to second-generation testing (US$ 18,866 vs US$ 17,200 per year). In summary, the use of third-generation tests largely clarified the uncertain results of second-generation tests; new additional positive patients were detected by third-generation assays compared to second-generation testing. Third-generation assays showed the association of duration of HD treatment and raised aminotransferase levels with anti-HCV antibody, as previously found by first- and second-generation assays. To date, third-generation screening and confirmatory assays seem extremely useful in the serologic survey for control of hepatitis C in HD centres without a considerable outlay.

AB - There is little information about the serologic survey for control of hepatitis C by using third-generation assays among chronic haemodialysis (HD) patients, and no analysis of costs has been made to this end. A serologic survey for control of hepatitis C was performed in 190 HD patients attending a single dialysis unit, using second- and third-generation assays. Costs of both serologic surveys were calculated. Anti-HCV prevalence tested by third-generation assays increased from 25% (48/190) to 28% (53/190) compared to second-generation testing; 56% (9/16) of patients showing uncertain findings by second-generation tests gave unequivocal results by third-generation assays; median duration of HD treatment and raised aminotransferase levels were positively associated (P = 0.004 and P = 0.012, respectively) with anti-HCV detected by third-generation assays. The serologic survey for control of hepatitis C in HD patients at our centre was slightly more expensive by third-generation assays compared to second-generation testing (US$ 18,866 vs US$ 17,200 per year). In summary, the use of third-generation tests largely clarified the uncertain results of second-generation tests; new additional positive patients were detected by third-generation assays compared to second-generation testing. Third-generation assays showed the association of duration of HD treatment and raised aminotransferase levels with anti-HCV antibody, as previously found by first- and second-generation assays. To date, third-generation screening and confirmatory assays seem extremely useful in the serologic survey for control of hepatitis C in HD centres without a considerable outlay.

KW - Analysis of costs

KW - Haemodialysis patients

KW - Third-generation HCV confirmatory assays

KW - Third-generation HCV screening assays

UR - http://www.scopus.com/inward/record.url?scp=0031046863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031046863&partnerID=8YFLogxK

U2 - 10.1093/ndt/12.2.298

DO - 10.1093/ndt/12.2.298

M3 - Article

C2 - 9132649

AN - SCOPUS:0031046863

VL - 12

SP - 298

EP - 303

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 2

ER -